Therapeutic Asset Ratings
245 results matching 1 filter
133,990 assets · 8,802 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Gtx-006
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
P4
BB
(65)
Bendamustine
Mantle Cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(65)
Surufatinib
Pancreas Cancer
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(65)
(+)-VINCRISTINE
Childhood Cancer
Tianjin Medical University Cancer Institute and Hospital
P2
BB
(65)
Eloxatin
Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(64)
Famitinib
EGFR Activating Mutation
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(64)
Pyrotinib
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(64)
Pyrotinib
Hormone Receptor Positive Malignant Neoplasm of Breast
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(64)
rc48-adc
Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
P3
BB
(64)
Cetuximab
Cetuximab
Tianjin Medical University Cancer Institute and Hospital
P3
B
(63)
Irinotecan
Brain Metastases
Tianjin Medical University Cancer Institute and Hospital
P3
B
(63)
Irinotecan
Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
P3
B
(63)
(+)-VINCRISTINE
Brain Metastases
Tianjin Medical University Cancer Institute and Hospital
P3
B
(63)
Cetuximab
BRAF V600E
Tianjin Medical University Cancer Institute and Hospital
P2
B
(63)
Benadryl
Advanced and Metastatic NSCLC
Tianjin Medical University Cancer Institute and Hospital
P3
B
(62)
HYDROMORPHON
Advanced and Metastatic NSCLC
Tianjin Medical University Cancer Institute and Hospital
P3
B
(62)
Ketorolac Tromethamine
Advanced and Metastatic NSCLC
Tianjin Medical University Cancer Institute and Hospital
P3
B
(62)
Irinotecan
Malignant Solid Tumor
Tianjin Medical University Cancer Institute and Hospital
P2
B
(62)
Irinotecan
Pediatric Cancer
Tianjin Medical University Cancer Institute and Hospital
P2
B
(62)
IMMUNOGLOBULIN G1, ANTI-(HUMANIZED MOUSE MONOCLONAL HR3 .BETA.1 CHAIN ANTI-HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR), DISULFIDE WITH HUMANIZED MOUSE MONOCLONAL HR3 .KAPPA.-CHAIN, DIMER
Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital
P3
B
(61)
Benadryl
Advanced Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
P3
B
(60)
Irinotecan
Intrahepatic Cholangiocarcinoma (Icc)
Tianjin Medical University Cancer Institute and Hospital
P3
B
(60)
Dc-Cik
First-line Treatment
Tianjin Medical University Cancer Institute and Hospital
P2
B
(60)
dll3-car-nk cells
Extensive Stage Lung Small Cell Cancer
Tianjin Medical University Cancer Institute and Hospital
P2
B
(60)
Iparomlimab
Iparomlimab and Tuvonralimab Injection
Tianjin Medical University Cancer Institute and Hospital
P2
B
(60)
Showing 26 to 50 of 245 assets
Previous
Page 2 of 10
Next